Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
AMP-activated protein kinase: the guardian of cardiac energy status
D. Grahame Hardie
D. Grahame Hardie
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):465-468. https://doi.org/10.1172/JCI22683.
View: Text | PDF
Commentary

AMP-activated protein kinase: the guardian of cardiac energy status

  • Text
  • PDF
Abstract

Several years ago it was proposed that the AMP-activated protein kinase cascade might protect cells against stresses that deplete cellular ATP. Young et al. have now directly tested this by studying the effects of ischemia and reperfusion in perfused hearts from mice expressing a dominant-negative mutant that suppresses the kinase activity in cardiac muscle. Compared with control hearts, the mutant hearts showed clear evidence for increased necrotic damage and increased apoptosis. These findings may have implications for the treatment of ischemic heart disease.

Authors

D. Grahame Hardie

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
How the dominant-negative mutant works. AMPK is an αβγ heterotrimer, and...
How the dominant-negative mutant works. AMPK is an αβγ heterotrimer, and the catalytic α subunit is not functional unless it is complexed with β and γ. Expression in cardiac myocytes of inactive, mutant α2 subunit (red) from a strong promoter (muscle creatine kinase) that gives high expression levels means that expression of the inactive α2 is much higher than that of the endogenous, active α1 and α2 subunits. Because the availability of the β and γ subunits is limiting, most of the heterotrimers formed will contain the inactive, mutant α2. The excess α subunits (not complexed with β and γ) are probably recognized by cellular machinery as misfolded proteins and degraded.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts